With the rise of fatty liver disease among IT professionals due to poor lifestyle choices, several simple steps can protect ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

Bariatric surgery reduces the progression to decompensated cirrhosis and the risk for major adverse liver outcomes, such as ...

BOSTON HEIGHTS, Ohio, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Arhaus, Inc. ("Arhaus” or the "Company”) (NASDAQ: ARHS), a growing lifestyle brand and omni-channel retailer of premium artisan-crafted home ...

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...